Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Johanna E. Markkanen"'
Autor:
Suvi Jauhiainen, Miia M. Roschier, Mark S. Johnson, Tiina Nieminen, Olli H. Laitinen, Annamari Alitalo, Tomi T. Airenne, Tiina A. Salminen, Kari J. Airenne, Lenita Viitanen, Johanna E. Markkanen, Seppo Ylä-Herttuala, Pyry I. Toivanen
Publikováno v:
Journal of Biological Chemistry. 284:16037-16048
Members of the vascular endothelial growth factor (VEGF) family play a pivotal role in angiogenesis and lymphangiogenesis. They are potential therapeutics to induce blood vessel formation in myocardium and skeletal muscle, when normal blood flow is c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcd4b2c1260b8719287d8f4ce22e418f
https://doi.org/10.1074/jbc.m109.001123
https://doi.org/10.1074/jbc.m109.001123
Autor:
Teemu Takalo, Seppo Ylä-Herttuala, Sanna Turpeinen, Svetlana Laidinen, Tommi Heikura, Johanna E. Markkanen, Emmi Eriksson, Markku T Nurminen, Kati Kinnunen, Mohan Babu, Helena Viita
Publikováno v:
Circulation Research. 102:177-184
Human 15-lipoxygenase-1 (15-LO-1) is an oxidizing enzyme capable of producing reactive lipid hydroperoxides. 15-LO-1 and its products have been suggested to be involved in many pathological conditions, such as inflammation, atherogenesis, and carcino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::009dba6291f28fd15d0e037683601a23
https://doi.org/10.1161/circresaha.107.155556
https://doi.org/10.1161/circresaha.107.155556
Autor:
Johannes Lyytikkä, Tuomas Tammela, Michael Jeltsch, Terhi Karpanen, Johanna E. Markkanen, Salla Keskitalo, Seppo Ylä-Herttuala, Kari Alitalo
Publikováno v:
Circulation Research. 100:1460-1467
Vascular endothelial growth factor (VEGF)-C and VEGF-D require proteolytic cleavage of the carboxy terminal silk-homology domain for activation. To study the functions of the VEGF-C propeptides, we engineered a chimeric growth factor protein, VEGF-CA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01f13168cd5e8a7c7974d5cf8249a6ef
https://doi.org/10.1161/01.res.0000269042.58594.f6
https://doi.org/10.1161/01.res.0000269042.58594.f6
Publikováno v:
Trends in Cardiovascular Medicine. 14:295-300
Stimulation of angiogenesis, arteriogenesis, and lymphangiogenesis (i.e., therapeutic vascular growth) is a new concept for the treatment of ischemic cardiovascular diseases. A wealth of information is already available about the mechanisms and media
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70ba05e5fab3dc2d5520579061a917d8
https://doi.org/10.1016/j.tcm.2004.09.001
https://doi.org/10.1016/j.tcm.2004.09.001
Autor:
Marja Hedman, Marcin Gruchała, Tommi Heikura, Antti Kivelä, Johanna E. Markkanen, Maija-Riitta Ordén, Tuomas T. Rissanen, Steven A. Stacker, Marc G. Achen, Seppo Ylä-Herttuala, Juha Hartikainen, Päivi Silvennoinen, Antti Hedman, Juha Rutanen
Publikováno v:
Circulation. 109:1029-1035
Background— It is unclear what is the most efficient vector and growth factor for induction of therapeutic vascular growth in the heart. Furthermore, the histological nature of angiogenesis and potential side effects caused by different vascular en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f864479dcd088a62039d45b1f2d2bb4b
https://doi.org/10.1161/01.cir.0000115519.03688.a2
https://doi.org/10.1161/01.cir.0000115519.03688.a2
Autor:
Pia Leppänen, Juha Rutanen, Mikko I. Kettunen, Mikko P. Turunen, Ismo Vajanto, Johanna E. Markkanen, Mari Niemi, Tuomas T. Rissanen, Katja Arve, Mikko Hiltunen, Esko Alhava, Risto A. Kauppinen, Seppo Ylä-Herttuala
Publikováno v:
The American Journal of Pathology. 160:1393-1403
Vascular endothelial growth factor (VEGF) is a hypoxia-inducible endothelial cell mitogen and survival factor. Its receptor VEGFR-2 (KDR/Flk-1) mediates these effects. We studied the expression of VEGF and VEGFR-2 in ischemic human and rabbit skeleta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fb5e9800cd1acc4a964b9186cdff324
https://doi.org/10.1016/s0002-9440(10)62566-7
https://doi.org/10.1016/s0002-9440(10)62566-7
Autor:
Outi Närvänen, Mikko I. Kettunen, Johanna E. Markkanen, Tuomas T. Rissanen, Linda Cashion, Ismo Vajanto, Gabor M. Rubanyi, Pekka Taipale, Seppo Ylä-Herttuala, Katja Arve, Risto A. Kauppinen, Marcin Gruchała, Suvi Jauhiainen, Juha Rutanen
Publikováno v:
The FASEB Journal. 17:100-102
Previous studies have shown that fibroblast growth factor (FGF)-1, FGF-2, and FGF-5 induce therapeutic angiogenesis. Here, we investigated the potential of FGF-4 for therapeutic neovascularization in comparison to vascular endothelial growth factor (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e89f5306fb0d02e051e28453495fc92
https://doi.org/10.1096/fj.02-0377fje
https://doi.org/10.1096/fj.02-0377fje
Autor:
Olli Gröhn, Henna Karvinen, Timo Liimatainen, Seppo Ylä-Herttuala, Tuomas T. Rissanen, Svetlana Laidinen, Timo Bengtsson, Johanna E. Markkanen, Petra Korpisalo
Publikováno v:
Cardiovascular research. 80(2)
Aims We investigated the effects of angiogenic gene therapy with adenoviral placental growth factor131 (AdPlGF) on aerobic capacity and exercise tolerance in a rabbit hindlimb ischaemia model. We also assessed whether strong angiogenic changes such a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a49a798ca90973c71e632f9c7a068fb0
https://pubmed.ncbi.nlm.nih.gov/18647755
https://pubmed.ncbi.nlm.nih.gov/18647755
Autor:
Katri Pajusola, Tuomas T. Rissanen, Juha Rutanen, Ilze Kokina, Hansruedi Büeler, Johanna E. Markkanen, Ivana Kholová, Tommi Heikura, Shalini Bhardwaj, Seppo Ylä-Herttuala, Marcin Gruchała, Himadri Roy, Kari Alitalo
Publikováno v:
The journal of gene medicine. 6(5)
Background Gene transfer offers considerable potential for altering vessel wall physiology and intervention in vascular disease. Therefore, there is great interest in developing optimal strategies and vectors for efficient, targeted gene delivery int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38a248336b59122b8834ff82d1e1a333
https://pubmed.ncbi.nlm.nih.gov/15133765
https://pubmed.ncbi.nlm.nih.gov/15133765
Autor:
Seppo Ylä-Herttuala, Tuomas T. Rissanen, Antti Puranen, Marcin Gruchała, Mikko I. Kettunen, Risto A. Kauppinen, Kari Alitalo, Johanna E. Markkanen, Ivana Kholová, Marc G. Achen, Tommi Heikura, Steven A. Stacker
Publikováno v:
Circulation research. 92(10)
Optimal angiogenic and lymphangiogenic gene therapy requires knowledge of the best growth factors for each purpose. We studied the therapeutic potential of human vascular endothelial growth factor (VEGF) family members VEGF-A, VEGF-B, VEGF-C, and VEG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbf860f4bdb965102720bb7e5958c46a
https://pubmed.ncbi.nlm.nih.gov/12714562
https://pubmed.ncbi.nlm.nih.gov/12714562